Roger G. Stoll PhD

Filings by Roger G. Stoll PhD span 3 companies, the busiest being Chelsea Therapeutics International, Ltd., Delcath Systems, Inc. and RespireRx Pharmaceuticals Inc. Over a trading history stretching from 16 November 2007 to 8 May 2020, the count stands at 40 filings.

On the market, this insider has only ever bought: 30 purchases, €246k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 7 share grants.

The median purchase comes to €4,167. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 4 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -73.6%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 8 May 2020, reports a transaction in Delcath Systems, Inc. The last purchase on record was published on 23 October 2018, which is 2,922 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.